secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2023-05-12T23:59:59+00:00
Accession:  0000950170-23-021809
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Atara Biotherapeutics EVP Global Head of R&D Jakob Dupont resigns, enters consulting agreement
--------------------------------------------------------------------------------

- Dr. Jakob Dupont, EVP Global Head of R&D, resigned effective May 12, 2023.
- Entered consulting agreement through Dec 31, 2023; monthly fees $15,000 through Aug 31 then $4,500, plus $300/hr excess.
- Outstanding equity awards will continue to vest during the consulting term.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000095017023021809/0000950170-23-021809-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000095017023021809/atra-20230512.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-021809

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer